Current Hypertension Reports

, Volume 2, Issue 1, pp 59–61

Hope gives reason for hope

  • Ernesto L. Schiffrin
Clinical Trials Review


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Goldblatt H, Lynch J, Hanzal RF, Summerville WW: Studies on experimental hypertension: the production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934, 59:347.CrossRefPubMedGoogle Scholar
  2. 2.
    Braun-Menéndez E, Fasciolo JC, Leloir LF, Muñoz JM: The substance causing renal hypertension. J Physiol 1940, 98:283.PubMedGoogle Scholar
  3. 3.
    Page IH, Helmer OM: A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin activator. J Exp Med 1940, 71:29.CrossRefPubMedGoogle Scholar
  4. 4.
    The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 25:293–302.Google Scholar
  5. 5.
    The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685–691.CrossRefGoogle Scholar
  6. 6.
    Cohn JN, Johnson G, Zeische S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303–310.PubMedCrossRefGoogle Scholar
  7. 7.
    Pfeffer MA, Braunwald E, Moyé LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992, 327:669–677.PubMedCrossRefGoogle Scholar
  8. 8.
    The AIRE Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinic evidence of heart failure. Lancet 1993, 342:821–828.Google Scholar
  9. 9.
    GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico III): GISSI-3: effect of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet 1994, 343:1115–1122.Google Scholar
  10. 10.
    Ambrosioni E, Borghi B: The effect of the ACE inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995, 332:80–85.PubMedCrossRefGoogle Scholar
  11. 11.
    Kober L, Torp-Pedersen C, Clarsen JE, et al.: A clinical trial of ACE inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995, 333:1670–1676.PubMedCrossRefGoogle Scholar
  12. 12.
    4th International Study of Infarct Survival Collaborative Group: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. ISIS-4. Lancet 1995, 345:669–685.CrossRefGoogle Scholar
  13. 13.
    Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. [N Engl J Med Web site]. Available at: 1.asp. [Early release-to be published 1/20/00].Google Scholar
  14. 14.
    Booz GW, Baker KM: Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension 1996, 28:635–640.PubMedGoogle Scholar
  15. 15.
    Geisterfer AAT, Peach MJ, Owens GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988, 62:749–756.PubMedGoogle Scholar
  16. 16.
    Yamada T, Horiuchi M, Dzau VJ: Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996, 93:156–160.PubMedCrossRefGoogle Scholar
  17. 17.
    Diep Q, Li JS, Schiffrin EL: In vivo study of the role of AT1 and AT2 angiotensin receptors in apoptosis in rat blood vessels. Hypertension 1999, 34:617–624.PubMedGoogle Scholar
  18. 18.
    Leri A, Claudio PP, Li Q, et al.: Stretch-mediated release of angiotensin II induces myocytes apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the bcl-2 to bax protein ratio in the cell. J Clin Invest 1998, 101:1326–1342.PubMedGoogle Scholar
  19. 19.
    Benetos A, Levy BI, Lacolley P, et al.: Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997, 17:3196–3201.PubMedGoogle Scholar
  20. 20.
    Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994, 4:1141–1148.Google Scholar
  21. 21.
    Laursen JB, Rajagopalan S, Galis Z, et al.: Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997, 95:588–593.PubMedGoogle Scholar
  22. 22.
    Huraux C, Makita T, Kurz S, et al.: Superoxide production, risk factors, and endothelium-dependent relaxations in human internal mammary arteries. Circulation 1999, 99:53–59.PubMedGoogle Scholar
  23. 23.
    Schiffrin EL, Deng LY, Larochelle P: Effects of a b-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994, 23:83–91.PubMedGoogle Scholar
  24. 24.
    Mancini GB: Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease. Am J Med 1998, 105:40S-47S.PubMedCrossRefGoogle Scholar
  25. 25.
    Schiffrin EL, Park JB, Intengan HD, Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin antagonist losartan. Circulation 1999, in press. Google Scholar
  26. 26.
    Yanagitani Y, Rakugi H, Okamura A, et al.: Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 1999, 33(pt 2):335–339.PubMedGoogle Scholar
  27. 27.
    Kranzhofer R, Schmidt J, Pfeiffer CA, et al.: Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999, 19:1623–1629.PubMedGoogle Scholar
  28. 28.
    Funakoshi Y, Ichiki T, Ito K, Takeshita A: Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension 1999, 34:118–125.PubMedGoogle Scholar
  29. 29.
    Han Y, Runge MS, Brasier AR: Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 1999, 84:695–703.PubMedGoogle Scholar
  30. 30.
    Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995, 95:995–1001.PubMedCrossRefGoogle Scholar
  31. 31.
    Larsson PT, Schwieler JH, Wallen NH, Hjemdahl P: Acute effects of angiotensin II on fibrinolysis in healthy volunteers. Blood Coagul Fibrinolysis 1999, 10:19–24.PubMedGoogle Scholar

Copyright information

© Current Science 2000

Authors and Affiliations

  • Ernesto L. Schiffrin
    • 1
  1. 1.Clinical Research Institute of MontrealMontrealCanada

Personalised recommendations